Saudi Journal of Ophthalmology
Volume 24, Issue 3 , Pages 87-94 , July 2010

Early Avastin management in acute retinal vein occlusion

Received 20 March 2010 ,Accepted 20 March 2010.

References 

  1. Alexander JB, Netan C. The latest trends in retinal vein occlusions. Retinal Physician. 2008;22–28
  2. Avitabile T, Longo A, Reibaldi A, et al. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol. 2005;140:695–702
  3. Battaglia Parodi M, Saviano S, Bergamini L, Ravalico G. Grid laser treatment of macular edema in macular branch retinal vein occlusion. Doc. Ophthalmol. 1999;97:427–431
  4. Battaglia Parodi M, Saviano S, Ravalico G, et al. Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch. Clin. Exp. Ophthalmol. 1999;237:1024–1027
  5. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2005;25:851–855
  6. Central Vein Occlusion Study Group . Natural history and clinical management of central retinal vein occlusion. Arch. Ophthalmol. 1997;115:486–491
  7. Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch. Clin. Exp. Ophthalmol. 2008;246:1241–1247
  8. Costa RA, Calucci D, Skaf M, et al. Optical coherence tomography 3: automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest. Ophthalmol. Vis. Sci. 2004;45:2399–2406
  9. Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007;27:141–149
  10. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am. J. Ophthalmol. 2007;144:864–871
  11. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology. 1983;90:458–474
  12. Hoerauf H. Branch retinal vein occlusion. In:  Joussen AM,  Gardner TW,  Kirchhof B,  Ryan SJ editor. Retinal Vascular Disease. Philadelphia: Springer; 2007;p. 467–506
  13. Hsu J, Kaiser RS, Sivalingam A, et al. Intravitreal bevacizumab (avastin) in central retinal vein occlusion. Retina. 2007;27:1013–1019
  14. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short- term study. Retina. 2006;26:279–284
  15. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch. Clin. Exp. Ophthalmol. 2009;247:27–33
  16. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye. 2005;19:65–71
  17. Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans. Am. Ophthalmol. Soc. 2000;98:133–143
  18. Klein R, Moss SE, Meuer SM, et al. The 15-year cumulative incidence of retinal vein occlusion. Arch. Ophthalmol. 2008;126(4):513–518
  19. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br. J. Ophthalmol. 2008;92:351–355
  20. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br. J. Ophthalmol. 2008;92:518–522
  21. Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA. Rebound macular edema following bevacizumab (Avastin). Retina. 2007;27:426–431
  22. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2007;114:835–854
  23. Moschos MM, Moschos M. Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc. Ophthalmol. 2008;116:147–152
  24. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch. Clin. Exp. Ophthalmol. 2006;244:309–315
  25. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular edema in branch retinal vein occlusion. Eye. 2008;22:42–48
  26. Noritatsu Y, Akitaka T, Atsushi S, et al. Retinal sensitivity after intravitreal injection of Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Retina. 2009;29:757–767
  27. Ozkiris A, Evereklioglu C, Erkilic K, Dogan H. Intravitreal triamcinolone acetonide for treatment of persistent macular edema in branch retinal vein occlusion. Eye. 2006;20:13–17
  28. Pe’er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. 1995;72:638–645
  29. Pe’er J, Folber R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor up-regulation in human central retinal vein occlusion. Ophthalmology. 1998;105:412–416
  30. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular edema secondary to retinal vein occlusion-twelve-month results of a prospective clinical trial. Br. J. Ophthalmol. 2009;93:452–456
  31. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27:419–425
  32. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr. Eye Res. 2008;33:111–131
  33. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthal. Surg. Lasers Imaging. 2005;36:336–339
  34. Sherif E. Intravitreal Bevacizumab treatment for macular edema secondary to central and branch retinal vein occlusion. J. Egypt. Ophthalmol. Soc. 2008;1:73–78
  35. Spandau U, Wickenhäuser A, Rensch F, Jonas J. Intravitreal bevacizumab for branch retinal vein occlusion. Acta Ophthalmol. Scand. 2007;85:118–119
  36. The Branch Vein Occlusion Study Group . Argon laser photocoagulation for macular edema in branch vein occlusion. Am. J. Ophthalmol. 1984;98:271–282
  37. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am. J. Ophthalmol. 2002;133:373–385
  38. Vinores SA, Youssri AI, Luna JD, et al. Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol. Histopathol. 1997;12:99–109
  39. Wu L, Arevalo JF, Roca JA, et al. Pan-American Collaborative Retina Study Group (PACORES) Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina. 2008;28:212–219

PII: S1319-4534(10)00047-0

doi: 10.1016/j.sjopt.2010.03.004

Saudi Journal of Ophthalmology
Volume 24, Issue 3 , Pages 87-94 , July 2010

Article Tools

* Image Usage & Resolution